Inevitable government cost-reduction measures, which may include stricter pricing policies, to slow market growth in the longer run. Much-needed investment in hospitals and growing wage demands to claim most available additional spending, thus hampering funding increases for pharmaceuticals. ...Inevitable government cost-reduction measures, which may include stricter pricing policies, to slow market growth in the longer run. Much-needed investment in hospitals and growing wage demands to claim most available additional spending, thus hampering funding increases for pharmaceuticals. Policy to remain focused on restraining pharmaceutical price growth, limiting the attractiveness of the market for importers. ...Bribery and corruption present in healthcare services. Eurozone risks relating to Greek bailout could impact on pharmaceutical market imports and exports via exchange rate fluctuations.
...In BMI s Q--- Pharmaceutical Risk/Reward Index (RRI) Latvia is ranked --th out of the -- markets in the Central and Eastern European (CEE) matrix with an improved score of --.- compared with the previous quarter (--.-). Latvia s score remains below the regional average of --.-, indicating the country s challenging business environment, particularly in terms of potential industry rewards and the potential impact of the eurozone crisis. ...In BMI s Q--- Pharmaceutical Risk/Reward Index (RRI) Latvia is ranked --th out of the -- markets in the Central and Eastern European (CEE) matrix with an improved score of --.- compared with the previous quarter (--.-). Latvia s score remains below the regional average of --.-, indicating the country s challenging business environment, particularly in terms of potential industry rewards and the potential impact of the eurozone crisis. Consequently, direct multinational operations are limited and domestic companies, such as Grindeks, have looked abroad for growth opportunities. ...Latvia s score remains below the regional average of --.-, indicating the country s challenging business environment, particularly in terms of potential industry rewards and the potential impact of the eurozone crisis. Consequently, direct multinational operations are limited and domestic companies, such as Grindeks, have looked abroad for growth opportunities.
...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...
...